Cargando…

Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial

The double-blind phase of the randomized ANRS IPERGAY trial, evaluating sexual activity-based oral HIV pre-exposure prophylaxis (PrEP), was conducted among high-risk men who have sex with men (MSM). Results showed an 86% (95% CI: 40–98) relative reduction in HIV incidence among participants with ten...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagaon-Teyssier, Luis, Suzan-Monti, Marie, Demoulin, Baptiste, Capitant, Catherine, Lorente, Nicolas, Préau, Marie, Mora, Marion, Rojas Castro, Daniela, Chidiac, Christian, Chas, Julie, Meyer, Laurence, Molina, Jean-Michel, Spire, Bruno, for the ANRS IPERGAY Study Group
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828609/
https://www.ncbi.nlm.nih.gov/pubmed/26883400
http://dx.doi.org/10.1080/09540121.2016.1146653
_version_ 1782426617308512256
author Sagaon-Teyssier, Luis
Suzan-Monti, Marie
Demoulin, Baptiste
Capitant, Catherine
Lorente, Nicolas
Préau, Marie
Mora, Marion
Rojas Castro, Daniela
Chidiac, Christian
Chas, Julie
Meyer, Laurence
Molina, Jean-Michel
Spire, Bruno
for the ANRS IPERGAY Study Group,
author_facet Sagaon-Teyssier, Luis
Suzan-Monti, Marie
Demoulin, Baptiste
Capitant, Catherine
Lorente, Nicolas
Préau, Marie
Mora, Marion
Rojas Castro, Daniela
Chidiac, Christian
Chas, Julie
Meyer, Laurence
Molina, Jean-Michel
Spire, Bruno
for the ANRS IPERGAY Study Group,
author_sort Sagaon-Teyssier, Luis
collection PubMed
description The double-blind phase of the randomized ANRS IPERGAY trial, evaluating sexual activity-based oral HIV pre-exposure prophylaxis (PrEP), was conducted among high-risk men who have sex with men (MSM). Results showed an 86% (95% CI: 40–98) relative reduction in HIV incidence among participants with tenofovir disoproxil fumarate–emtricitabine vs. placebo. The present pooled analysis aimed to analyze (i) participants’ adherence to the prescribed treatment and/or condom use during sexual intercourse and (ii) sexual behavior during the double-blind phase of the study. Four hundred MSM were enrolled in the trial. Every 2 months they completed online questionnaires collecting sexual behavior and PrEP adherence data regarding their most recent sexual intercourse. A total of 2232 questionnaires (M0–M24) were analyzed. Changes over time were evaluated using a mixed model accounting for multiple measures. Irrespective of sexual partner and practice type, on average, 42.6% (min: 32.1–max: 45.8%) reported PrEP use only during their most recent episode of sexual intercourse; 29% (22.9–35.6%) reported both PrEP and condom use; 11.7% (7.2–18.9%) reported condom-use only, and 16.7% (10.8–29.6%) reported no PrEP or condom use with no significant change during the study. Scheduled (i.e., correct) PrEP use was reported on average by 59.0% (47.2–68.5%) of those reporting PrEP use during their most recent sexual intercourse. Overall, 70.3% (65.3–79.4%) and 69.3% (58.3–75.4%) of participants reported, respectively, condomless anal and condomless receptive anal intercourse during their most recent sexual encounter without significant change during follow-up. Overall, on average 83.3% (min: 70.4–max: 89.2%) of participants protected themselves by PrEP intake or condom use or both during the trial, and no increase in at-risk sexual practices was observed. None of these indicators showed significant trend during the follow-up, although we found a tendency toward decrease (p = .19) of the median number of sexual partners strengthening the absence of behavioral disinhibition. On-demand PrEP within a comprehensive HIV prevention package could improve prevention in MSM.
format Online
Article
Text
id pubmed-4828609
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-48286092016-04-27 Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial Sagaon-Teyssier, Luis Suzan-Monti, Marie Demoulin, Baptiste Capitant, Catherine Lorente, Nicolas Préau, Marie Mora, Marion Rojas Castro, Daniela Chidiac, Christian Chas, Julie Meyer, Laurence Molina, Jean-Michel Spire, Bruno for the ANRS IPERGAY Study Group, AIDS Care Articles The double-blind phase of the randomized ANRS IPERGAY trial, evaluating sexual activity-based oral HIV pre-exposure prophylaxis (PrEP), was conducted among high-risk men who have sex with men (MSM). Results showed an 86% (95% CI: 40–98) relative reduction in HIV incidence among participants with tenofovir disoproxil fumarate–emtricitabine vs. placebo. The present pooled analysis aimed to analyze (i) participants’ adherence to the prescribed treatment and/or condom use during sexual intercourse and (ii) sexual behavior during the double-blind phase of the study. Four hundred MSM were enrolled in the trial. Every 2 months they completed online questionnaires collecting sexual behavior and PrEP adherence data regarding their most recent sexual intercourse. A total of 2232 questionnaires (M0–M24) were analyzed. Changes over time were evaluated using a mixed model accounting for multiple measures. Irrespective of sexual partner and practice type, on average, 42.6% (min: 32.1–max: 45.8%) reported PrEP use only during their most recent episode of sexual intercourse; 29% (22.9–35.6%) reported both PrEP and condom use; 11.7% (7.2–18.9%) reported condom-use only, and 16.7% (10.8–29.6%) reported no PrEP or condom use with no significant change during the study. Scheduled (i.e., correct) PrEP use was reported on average by 59.0% (47.2–68.5%) of those reporting PrEP use during their most recent sexual intercourse. Overall, 70.3% (65.3–79.4%) and 69.3% (58.3–75.4%) of participants reported, respectively, condomless anal and condomless receptive anal intercourse during their most recent sexual encounter without significant change during follow-up. Overall, on average 83.3% (min: 70.4–max: 89.2%) of participants protected themselves by PrEP intake or condom use or both during the trial, and no increase in at-risk sexual practices was observed. None of these indicators showed significant trend during the follow-up, although we found a tendency toward decrease (p = .19) of the median number of sexual partners strengthening the absence of behavioral disinhibition. On-demand PrEP within a comprehensive HIV prevention package could improve prevention in MSM. Taylor & Francis 2016-03-24 2016-02-17 /pmc/articles/PMC4828609/ /pubmed/26883400 http://dx.doi.org/10.1080/09540121.2016.1146653 Text en © 2016 The Author(s). Published by Taylor & Francis. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/Licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Articles
Sagaon-Teyssier, Luis
Suzan-Monti, Marie
Demoulin, Baptiste
Capitant, Catherine
Lorente, Nicolas
Préau, Marie
Mora, Marion
Rojas Castro, Daniela
Chidiac, Christian
Chas, Julie
Meyer, Laurence
Molina, Jean-Michel
Spire, Bruno
for the ANRS IPERGAY Study Group,
Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial
title Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial
title_full Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial
title_fullStr Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial
title_full_unstemmed Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial
title_short Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial
title_sort uptake of prep and condom and sexual risk behavior among msm during the anrs ipergay trial
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828609/
https://www.ncbi.nlm.nih.gov/pubmed/26883400
http://dx.doi.org/10.1080/09540121.2016.1146653
work_keys_str_mv AT sagaonteyssierluis uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT suzanmontimarie uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT demoulinbaptiste uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT capitantcatherine uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT lorentenicolas uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT preaumarie uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT moramarion uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT rojascastrodaniela uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT chidiacchristian uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT chasjulie uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT meyerlaurence uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT molinajeanmichel uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT spirebruno uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial
AT fortheanrsipergaystudygroup uptakeofprepandcondomandsexualriskbehavioramongmsmduringtheanrsipergaytrial